These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 36800019)

  • 21. Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors: A Systematic Literature Review.
    Ghosh N; Chan KK; Jivanelli B; Bass AR
    J Clin Rheumatol; 2022 Mar; 28(2):e498-e505. PubMed ID: 34371516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Distinctive Disease Entity of Neurological Adverse Events Associated with Immune Checkpoint Inhibitors].
    Seki M; Suzuki S
    Brain Nerve; 2021 Jan; 73(1):35-46. PubMed ID: 33361512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
    Yao S; Li X; Nong J; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
    Diamanti L; Picca A; Bini P; Gastaldi M; Alfonsi E; Pichiecchio A; Rota E; Rudà R; Bruno F; Villani V; Galiè E; Vogrig A; Valente M; Zoccarato M; Poretto V; Giometto B; Cimminiello C; Del Vecchio M; Marchioni E
    Neurol Sci; 2022 Mar; 43(3):2031-2041. PubMed ID: 34424427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis.
    Xu M; Nie Y; Yang Y; Lu YT; Su Q
    Neurologist; 2019 May; 24(3):75-83. PubMed ID: 31045716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review.
    Zammit F; Seront E
    Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Checkpoint Inhibitors and Neurotoxicity.
    Zhao Z; Zhang C; Zhou L; Dong P; Shi L
    Curr Neuropharmacol; 2021; 19(8):1246-1263. PubMed ID: 33380303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders.
    Aoun R; Gratch D; Kaminetzky D; Kister I
    Curr Neurol Neurosci Rep; 2023 Nov; 23(11):735-750. PubMed ID: 37870664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
    Cappelli LC; Bingham CO
    Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors.
    Jordan B; Benesova K; Hassel JC; Wick W; Jordan K
    ESMO Open; 2021 Dec; 6(6):100317. PubMed ID: 34839103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
    Seki M; Kitano S; Suzuki S
    Cancer Immunol Immunother; 2022 Apr; 71(4):769-775. PubMed ID: 34515815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature.
    Fan S; Ren H; Zhao L; Yin J; Feng G; Wang J; Guan H
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):291-298. PubMed ID: 32893999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint inhibitors induced side effects of the peripheral nervous system.
    Hundsberger T; Schreiner B; Roth P
    Curr Opin Neurol; 2023 Oct; 36(5):427-431. PubMed ID: 37639489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies.
    Salim A; Tapia Rico G; Shaikh A; Brown MP
    Expert Opin Biol Ther; 2021 Sep; 21(9):1237-1251. PubMed ID: 33645372
    [No Abstract]   [Full Text] [Related]  

  • 37. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
    Zhou L; Wei X
    Front Immunol; 2021; 12():701951. PubMed ID: 34504488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.
    Nassar AH; El Zarif T; Khalid AB; Rahme S; Zhong C; Kwak L; Salame M; Farhat EB; Freeman D; El-Am E; Ravishankar A; Ahmad B; Nana FA; Kaldas D; Naqash AR; Sharon E; LeBoeuf NR; Cortellini A; Malgeri A; Gupta S; Al-Hader A; Sparks JA; Linnoila J; Hamnvik OR; Mouhieddine TH; Marron T; Parikh K; McKay RR; Dilling T; Choueiri TK; Adib E; Najem E; Kim SY; Sonpavde G
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38448038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel uses of complement inhibitors in myasthenia gravis-Two case reports.
    Zadeh S; Price H; Drews R; Bouffard MA; Young LH; Narayanaswami P
    Muscle Nerve; 2024 Mar; 69(3):368-372. PubMed ID: 38205840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.